Regenerative Medicine for the Referring Physician: A 2026 Clinical Primer for Primary Care, Sports Medicine, Family Medicine, Dermatology, and Internal Medicine on PRP, Stem Cell, Exosome, Peptide, and IV Nutritional Therapy in Colombia — Indications, Evidence Quality, INVIMA Regulatory Framework, Patient Selection, Pre-Procedure Workup, Red Flags to Counsel Patients On, and the Referral Pathway to a Verifiable Regenerative Practice in Medellín

Introduction: The Referring Physician's Dilemma

Every plan is personalized. Message us on WhatsApp and we'll send your quote after reviewing your case.

This 2026 clinical primer is the companion piece written for the other audience: the referring physician — the primary care doctor, the family medicine practitioner, the sports medicine specialist, the dermatologist, the internal medicine physician — who increasingly gets the patient question "Doctor, what do you think about stem cells?" or "Should I do PRP for my knee?" or "My friend went to Medellín for a regenerative program — is it legitimate?" and needs a clinical primer rather than a marketing brochure to give a substantive answer.

The framing is honest. Some of regenerative medicine is well-supported by the evidence. Some of it is preliminary. Some of it is experimental. Some of the marketing has outrun the evidence. A referring physician who has read this primer should be able to:

• Distinguish well-supported indications from preliminary or experimental ones
• Apply the same verification framework to a regenerative practice that they would apply to any specialty referral
• Counsel patients on red flags before they book
• Order the appropriate pre-procedure workup in their own clinic
• Receive proper documentation back from the regenerative practice
• Oversee post-procedure care with substantive understanding of what was done

This piece is the physician-to-physician version of the four patient-facing verification companions (exosome sourcing, stem cell volume, PRP variability, IV therapy). Same framework. Different audience. Different vocabulary.

The Regenerative Medicine Landscape in 2026: Clinical Reality vs Marketing

The honest summary for a referring physician in 2026:

Reasonably well-supported (with caveats):

• PRP for knee osteoarthritis (modest effect sizes, dose-dependent, system-dependent, not a substitute for joint replacement when indicated)
• PRP for lateral epicondylitis (reasonably supported, modest effect)
• PRP for plantar fasciitis (reasonably supported)
• Microfragmented adipose injection for knee OA (growing evidence base, lower risk than expanded MSC protocols)
• Hair restoration with PRP for androgenetic alopecia (modest effect, adjunctive to standard therapy)
• Microneedling with PRP for skin rejuvenation (cosmetic indication, reasonable safety, modest effect)
• IV nutritional therapy for documented deficiencies, fatigue indications meeting Myers Cocktail criteria, and as adjunct in regenerative protocols
• Peptide therapy in specific indications (GLP-1 class for metabolic disease per FDA-approved use, PT-141 for sexual dysfunction in specific patient populations, BPC-157 with growing soft tissue evidence base — albeit largely preclinical to date — and physician-supervised use under appropriate consent)

Preliminary or developing evidence base:

• Adipose-derived stromal vascular fraction (SVF) for various orthopedic, dermatologic, and systemic indications
• Allogeneic exosome therapy (umbilical cord-derived) — early but growing literature, sourcing transparency is the dominant clinical question
• Stem cell therapy for autoimmune conditions (preliminary, requires careful patient selection)
• Stem cell therapy for neurological conditions (highly preliminary in most indications, requires very careful expectation-setting)
• NAD+ IV for cognitive and energy indications (mechanistic plausibility, limited high-quality RCT data)

Experimental or marketed beyond the evidence:

• Stem cells "for everything" framing
• Exosomes marketed as cures for chronic disease
• IV therapy marketed primarily for hangover or nightlife recovery as a quasi-medical service
• Single-protocol "stem cell packages" applied identically regardless of indication
• Cellular therapy for indications without published case series or trial data

A referring physician who internalizes the above can have a substantive first conversation with a patient considering regenerative medicine without needing to cite specific papers. The pattern recognition is what matters: well-supported → preliminary → experimental → marketed-beyond-evidence is the gradient, and the patient should be on the appropriate place on that gradient given the indication.

Mechanisms: Stem Cells, Growth Factors, Exosomes, Paracrine Signaling

The mechanism framework that matters clinically:

Stem cells (autologous adipose-derived MSC) and SVF

• Heterogeneous cell population including MSCs, pericytes, endothelial progenitors, regulatory T cells
• Acts predominantly via paracrine signaling — the cells release growth factors, cytokines, and exosomes locally that modulate the microenvironment, recruit endogenous repair cells, modulate inflammation, and promote tissue remodeling
• The historical framing that injected MSCs "differentiate into the target tissue" is now understood to be a minor fraction of the mechanism for most indications. Paracrine signaling and immunomodulation appear to be the dominant mechanisms.
• This matters clinically because cell number, cell viability, and the local microenvironment all influence outcomes — and because the paracrine model explains why exosomes (which capture the secreted signal without the cell itself) have a plausible mechanism of action.

Growth factors and cytokines (PRP)

• Platelets contain alpha granules that release PDGF, TGF-β, VEGF, EGF, IGF, FGF and a long list of other signaling proteins on activation
• The growth factor profile of a PRP preparation depends on platelet concentration, leukocyte content (LR-PRP vs LP-PRP), red blood cell content, activation method, and patient factors (medications, age, comorbidities, baseline platelet count)
• Effect sizes in clinical literature are dose-dependent and system-dependent — a critical clinical implication is that "PRP" is not a single product, and outcomes data published with one preparation system do not necessarily transfer to another
• See the PRP Variability companion guide for the eight bedside questions that determine what's actually in the tube

Exosomes (extracellular vesicles)

• Membrane-bound vesicles 30–150 nm in diameter that act as cell-to-cell communication carriers
• Cargo includes proteins, mRNA, miRNA, lipids
• The clinical promise: capture the paracrine signal of stem cells in a cell-free, more easily characterized product that is easier to ship, store, and dose
• The clinical caveat: the regulatory, sourcing, and quality landscape is still maturing; the dominant clinical question for any exosome product is where it came from and how it was characterized
• See the Exosome Sourcing companion guide for the eight bedside questions on allogeneic biologics

Peptides

• A heterogeneous class of short amino acid sequences with diverse mechanisms (GLP-1 receptor agonists, melanocortin receptor agonists, growth hormone secretagogues, copper-peptide complexes, neuropeptides)
• Some are well-characterized FDA-approved drugs (the GLP-1 class for metabolic disease)
• Some have growing but preliminary evidence bases (BPC-157, TB-500 for soft tissue repair; PT-141 for sexual dysfunction; GHK-Cu for skin and wound healing)
• Some are largely supported by mechanistic plausibility and case series rather than robust RCT data
• The regulatory framework matters: in Colombia, INVIMA-registered compounding pharmacies are the appropriate source

Modality-by-Modality Clinical Primer

Platelet-Rich Plasma (PRP)

Mechanism: Platelet-derived growth factor delivery and modulation of local inflammatory and repair processes.

Best-supported indications: Knee osteoarthritis (modest effect, dose-dependent), lateral epicondylitis, plantar fasciitis, androgenetic alopecia (adjunctive), facial rejuvenation (microneedling-PRP for cosmetic indication).

Preparation system variability is the dominant clinical question. Single-spin vs double-spin, leukocyte-rich vs leukocyte-poor, concentration achieved (typically reported as multiples of baseline platelet count, with 3–7x baseline considered the therapeutic range for most musculoskeletal indications, though this varies by indication), final volume, activation method. A serious referring physician should ask the receiving clinic which system, what concentration, and which leukocyte profile.

Pre-procedure considerations: Hold NSAIDs typically 7 days pre-procedure. Hold corticosteroid injections 4–6 weeks pre-procedure. Verify CBC and platelet count are within normal range. Document medications including anticoagulants.

Post-procedure considerations: Hold NSAIDs typically 2 weeks post-procedure (the acute inflammatory response is part of the mechanism). Activity modification per indication. Series of 1–3 injections typically separated by 4–6 weeks.

Cross-link: PRP Variability — What's Actually in Your Tube? (2026) for the full preparation system framework.

Autologous Stem Cells (Adipose-Derived MSC, SVF)

Mechanism: Predominantly paracrine signaling and immunomodulation, with a minor contribution from cellular differentiation in some indications.

Best-supported indications: Microfragmented adipose injection for knee OA (growing evidence base, lower processing complexity, lower risk than expanded MSC). Adipose-derived SVF for various orthopedic indications. Adipose-derived MSC microinjection for systemic indications (paracrine and immunomodulatory).

Cell processing facility infrastructure is the dominant clinical question. A referring physician should ask: Where is the cell processing performed? Is the laboratory accredited? Who performs the processing? What is the cell viability documented at administration? What is the cell count? What is the procedural volume of the practice (the volume framework matters)?

Pre-procedure workup: CBC, comprehensive metabolic panel, lipid panel, HbA1c, vitamin D, ferritin. Hepatitis serologies and HIV when allogeneic biologics are in the protocol or when the practice's standard pre-procedure panel includes them. Pregnancy test when relevant. Cardiac history and ECG when general anesthesia is involved or when the protocol includes other interventions requiring cardiac clearance.

Post-procedure considerations: Activity modification per indication. Follow-up imaging or labs per the regenerative practice's protocol. The referring physician should expect to receive the operative/procedure note, tissue processing documentation, and post-procedure protocol.

Cross-link: Volume Beats Credentials: The 2026 Stem Cell Clinic Verification Framework (2026) for the procedural infrastructure framework.

Allogeneic Exosomes

Mechanism: Extracellular vesicle delivery of paracrine signal molecules.

Indication landscape: Adjunctive to other regenerative protocols. Topical application post-microneedling for cosmetic indications. Investigational use for various systemic indications under appropriate consent and with realistic expectation-setting.

Sourcing transparency is the dominant clinical question. Allogeneic biologics — exosomes are typically derived from umbilical cord MSCs — require explicit sourcing documentation. A referring physician should expect: the source laboratory or manufacturer, the FDA registration status of the manufacturing facility (if US-sourced) or INVIMA registration status (if Colombia-sourced), lot number documentation, characterization data (particle size distribution, particle concentration, marker characterization), sterility validation, and donor screening framework.

Pre-procedure considerations: Standard pre-procedure workup as for the index protocol the exosomes are adjunctive to. Patient consent should explicitly address the allogeneic nature, the sourcing, and the regulatory framework.

Cross-link: Exosome Therapy in Colombia — What's Actually in That Vial? (2026) for the full sourcing transparency framework.

Peptide Therapy

Mechanism: Diverse — receptor-specific signaling depending on the peptide class.

Indication-specific framing:

• GLP-1 class (semaglutide, tirzepatide, retatrutide): Metabolic disease per FDA-approved or evidence-based use; appropriate workup and monitoring including pancreatic, thyroid, gallbladder considerations; documented contraindications.
• BPC-157 and TB-500: Soft tissue repair indications, growing literature predominantly preclinical with case series in clinical use; physician-supervised use under appropriate consent.
• PT-141 (bremelanotide): Hypoactive sexual desire disorder, FDA-approved indication; appropriate cardiovascular screening.
• GHK-Cu: Skin, hair, wound healing — primarily topical and injectable in cosmetic contexts.
• NAD+ (IV or subcutaneous): Energy, longevity, recovery indications; evidence base is mechanistic and emerging clinical literature; IV NAD+ requires slow infusion (2–4 hours).
• KLOW (combination protocol): Investigational combination protocol; physician-supervised use.

INVIMA framework: In Colombia, peptide therapy should be sourced from INVIMA-registered compounding pharmacies with documented chain of custody. See the Peptide Therapy in Colombia: INVIMA Standards companion guide.

Pre-procedure workup: Indication-specific. Metabolic panel, lipid panel, HbA1c for GLP-1 class. Consider hormonal workup (testosterone, thyroid) for indications where this is relevant. Document concurrent medications.

IV Nutritional Therapy

Mechanism: Direct delivery of nutritional and pharmacologic substrate via IV route, bypassing oral absorption limitations.

Best-supported clinical indications: Documented nutritional deficiencies, Myers Cocktail per documented criteria, NAD+ IV for energy/longevity indications, high-dose vitamin C in oncology adjunct contexts under appropriate supervision, glutathione for oxidative stress and hepatic indications, hydration and electrolyte support post-procedure.

Pre-procedure workup: Comprehensive metabolic panel for all IV protocols. G6PD status mandatory before high-dose vitamin C IV (oxidative hemolysis risk in deficient patients). Renal function for NAD+ and high-volume protocols. Cardiac history and ECG when chelation is in the protocol.

Compounding pharmacy verification: INVIMA-registered compounding source, lot-level traceability, ingredient source documentation, sterility validation.

Cross-link: Medical IV Therapy in Medellín: What's Actually in Your Drip? (2026) for the full IV verification framework.

Patient Selection by Indication

A referring physician applying basic clinical judgment can identify good candidates and clear non-candidates before any referral.

Generally good candidates:

• Patients with documented indication appropriate to the proposed regenerative modality
• Patients who have completed appropriate first-line therapy (or have a documented contraindication to it) and are at the appropriate decision point for an adjunctive or alternative regenerative intervention
• Patients with realistic expectations about effect size and timeline (most regenerative effects develop over 4–12 weeks and are modest in most musculoskeletal indications)
• Patients without active infection at the proposed treatment site
• Patients with adequate baseline labs documenting the absence of contraindications
• Patients who can comply with the post-procedure protocol (activity modification, follow-up, possible repeat sessions)

Generally not candidates:

• Patients seeking guarantees or cures (these are not on the table for any regenerative modality)
• Patients with active malignancy without explicit oncology coordination (some protocols are adjunctive, others are contraindicated)
• Patients with active untreated infection
• Patients with severe immunosuppression where biologic administration warrants explicit specialist coordination
• Patients with severe coagulopathy or on anticoagulation that cannot be safely paused
• Pregnancy and lactation: case-by-case for most protocols, with documented informed consent
• Patients with the indication that is structural and clearly requires a definitive procedure (advanced bone-on-bone OA where joint replacement is indicated; structural rotator cuff tear requiring surgical repair) — regenerative therapy in these contexts is at best adjunctive
• Patients seeking regenerative therapy as a substitute for evidence-based standard care for a serious condition

Pre-Procedure Workup the Referring Physician Can Order

Many serious regenerative practices request a defined pre-procedure panel from the referring physician. The patient is better served when this work is done before the consultation rather than during the visit.

Standard pre-procedure panel (most regenerative protocols):

• CBC with platelet count
• Comprehensive metabolic panel
• Lipid panel
• HbA1c
• Vitamin D 25-OH
• Ferritin
• TSH

Add for high-dose vitamin C IV protocols:

• G6PD quantitative

Add for IV protocols with high volume or NAD+:

• Creatinine and eGFR (already in CMP)
• Magnesium
• Electrolyte panel

Add for chelation protocols:

• ECG
• Documented metal burden (urine or blood metal panel as appropriate)
• Cardiac history documented

Add when allogeneic biologics are in the protocol:

• Hepatitis B and C serologies
• HIV serology
• The specific protocol may require additional infectious disease screening per the receiving clinic's standard

Add for relevant indications:

• Pregnancy test (when applicable)
• Hormonal panel (testosterone, estradiol, thyroid) when peptide therapy is in the protocol and indication is relevant
• Imaging: MRI for joint indications, photographic documentation for cosmetic indications, baseline imaging for the specific anatomic site being treated

The INVIMA Regulatory Framework in Colombia

For a referring physician outside Colombia who is being asked about a regenerative practice in Medellín, the INVIMA framework is the appropriate regulatory question.

INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos) is the Colombian regulatory equivalent of the FDA. It oversees:

• Pharmaceutical manufacturing including compounding pharmacy
• Medical device approval and post-market surveillance
• Cellular and tissue therapy regulatory framework
• Food and consumer product regulation

For a regenerative practice in Colombia, the appropriate INVIMA verification questions are:

• Is the cell processing facility INVIMA-registered?
• Are the compounded peptide products sourced from INVIMA-registered compounding pharmacies?
• Are the IV preparations sourced from INVIMA-registered compounding pharmacies?
• Are the medical devices used (e.g., adipose harvesting equipment, IV pumps, microneedling devices) INVIMA-approved?
• Is the practice operating under the appropriate Habilitación health authority operational license?

A serious Colombian regenerative practice will produce these documents on request without difficulty. A practice that cannot produce them is operating outside the regulatory framework, which is itself a clinical question for the referring physician.

Red Flags the Referring Physician Should Counsel Patients On

The referring physician is well-positioned to give patients pre-flight reality-checking that is harder to deliver after the patient has already paid the deposit. The red flags to counsel patients on:

• Cannot name the cell processing facility or source laboratory by name
• Cannot produce INVIMA registration documentation on request
• Single-protocol pricing applied identically to every indication ("our stem cell package is $X" without indication-specific pricing)
• No published procedural volume or adverse event tracking
• Mobile-only services with no clinical infrastructure (especially for IV protocols)
• Marketing language that promises cures, guarantees, or "miracle" outcomes
• No medical responsibility nominated (no specific physician with documented responsibility for the patient's care)
• Refusal to send the operative/procedure note and tissue processing documentation back to the referring physician
• Refusal to provide pre-procedure laboratory requirements list in advance
• Same-day "consultation and procedure" framework for any biologic intervention (no proper informed consent process)
• Marketing emphasis on hangover, nightlife recovery, or wellness-tourism positioning rather than clinical indication
• Cell counts or potency claims that exceed the plausible biological maximum for the harvest method described
• Claims that "we've never had any complications" with any procedural volume that would make that statistically improbable

The Eight Bedside Questions Translated to a Physician-to-Physician Verification Checklist

For the referring physician verifying a regenerative practice, the eight questions translate to:

1. Cell processing or compounding facility identification: The specific facility name, regulatory registration (INVIMA / FDA-registered as applicable), and accreditation status.
2. Lot or batch traceability: Lot-level documentation for biologic products; batch documentation for compounded products.
3. Ingredient/source documentation: For autologous products, the harvest and processing protocol; for allogeneic products, the source laboratory and donor screening framework.
4. Sterility validation and product expiration: Documented sterility testing and clear expiration dating per product type.
5. Indication-specific protocol justification: Documented clinical indication and dosing rationale specific to the patient's presentation rather than a one-size-fits-all package.
6. Procedural technique documentation: For PRP, the preparation system and concentration; for stem cells, the harvest, processing, and cell count; for IV, the infusion rate and duration; for peptides, the dosing schedule.
7. Pre-procedure workup completed: Confirmation that the indication-appropriate workup has been completed (G6PD for high-dose vitamin C, renal for NAD+ and high-volume IV, cardiac for chelation, infectious disease panel for allogeneic biologics, etc.).
8. Named medical responsibility and adverse event tracking: A specific physician with documented responsibility for the patient's care, and a documented adverse event tracking system with willingness to disclose historical rates.

The Referral Pathway to YouMedicine

For a referring physician considering YouMedicine as a regenerative referral destination for a patient, the pathway:

1. Initial physician-to-physician contact via wellness@youmedicine.co or +57 324 576 1913, with the patient's indication, relevant history, and the referring physician's specific clinical question.
2. Documentation exchange: The pre-procedure workup requirements list (relative to the proposed protocol), the protocol description, the INVIMA documentation, the cell processing facility documentation, and the practice's standard pre-procedure consent framework will be sent to the referring physician.
3. Patient pre-procedure workup completed by the referring physician in their own clinic, with results sent to YouMedicine in advance of the patient's travel.

Every plan is personalized. Message us on WhatsApp and we'll send your quote after reviewing your case.

1. Documentation sent back to the referring physician: The operative or procedure note, the tissue processing documentation (for autologous protocols, the cell count, viability, processing technique; for allogeneic protocols, the lot number and source documentation), the photographic documentation when relevant, the post-procedure protocol, and the recommended follow-up schedule.
2. Post-procedure care oversight by the referring physician with the protocol provided, with availability of the YouMedicine team for any clinical questions during the recovery period.

The referring physician should expect the regenerative practice to behave like any specialty referral: documentation in, documentation out, clear handoff back for ongoing care.

Frequently Asked Questions from Referring Physicians

1. Is the evidence base for stem cell therapy at the level where I should be referring patients?

For specific musculoskeletal indications (microfragmented adipose for knee OA, autologous adipose-derived MSC microinjection in selected systemic indications), the evidence base is reasonable for adjunctive use with appropriate patient selection and expectation-setting. For broader systemic indications (autoimmune, neurological), the evidence base is preliminary and patient selection requires careful judgment. For "stem cells for everything" framing, the evidence does not support that level of generalization.

2. What is the liability landscape for me as the referring physician?

The same as any specialty referral. The referring physician is responsible for the appropriateness of the referral (documenting the indication, the workup, the discussion of options including non-regenerative alternatives, the patient's informed decision to pursue the referral). The receiving practice is responsible for the procedure itself. The referring physician oversees post-procedure care per the protocol provided.

3. What happens if my patient returns with a complication?

The expectation is the same as for any specialty referral: contact the receiving practice (wellness@youmedicine.co, +57 324 576 1913) for clinical consultation, manage the acute issue per standard of care in the patient's local clinic, and document the event in the patient's record. A serious regenerative practice will respond promptly to complication consultations and will participate in adverse event documentation.

4. How does a Colombian regenerative practice differ from a domestic US PRP/stem cell offering?

The dominant differences are: (a) regulatory framework (INVIMA vs FDA), which means the source documentation is different but the verification logic is the same; (b) cost structure (Colombian practices typically operate at substantially lower cost than US comparable offerings, which is a function of healthcare cost economics rather than quality); (c) protocol breadth (Colombian regenerative practices often offer protocols — autologous adipose-derived MSC microinjection, allogeneic exosomes, expanded peptide formularies — that are less commonly offered in the US due to FDA framework differences); (d) the patient's willingness to travel changes the pre-flight verification framework (which is the entire purpose of the patient-facing verification quartet on this site).

5. What about the patient who wants stem cells for an indication where the evidence is very preliminary?

The honest physician-to-physician answer: counsel the patient on the preliminary nature of the evidence, the realistic effect size given the literature, the cost in time and money, the alternative or adjunctive interventions that may be appropriate, and the importance of having appropriately calibrated expectations. A serious regenerative practice will participate in this expectation-setting rather than making promises that the evidence does not support.

6. Can I get the operative note and tissue processing documentation in English?

Yes. YouMedicine sends documentation in English as standard for international referrals.

7. What if my patient has G6PD deficiency and high-dose vitamin C is in the proposed protocol?

The protocol should be modified or the high-dose vitamin C component substituted. Standard-dose vitamin C and other antioxidant components (glutathione, NAC) can be appropriate alternatives.

8. What is the appropriate pre-procedure communication if my patient is on anticoagulation, immunosuppression, or has significant comorbidity?

Direct physician-to-physician contact via wellness@youmedicine.co or +57 324 576 1913 is appropriate. The protocol may need modification (timing of procedure relative to anticoagulation pause, modifications for immunosuppression, additional cardiac or infectious disease screening for relevant comorbidities). This conversation should happen before the patient travels.

9. How does the Stem Cell Express program differ from a single-procedure referral?

Every plan is personalized. Message us on WhatsApp and we'll send your quote after reviewing your case.

10. What is the expected effect size and timeline I should communicate to my patient?

Indication-dependent. For musculoskeletal indications (PRP, microfragmented adipose), modest effect sizes developing over 4–12 weeks with possible repeat sessions. For cosmetic indications (microneedling-PRP, exosome facial), gradual improvement over a series of treatments. For systemic indications (adipose-derived MSC microinjection for general wellness/longevity), the effect framework is more modest and longer-timeline. For experimental indications, expectations should be explicitly preliminary. A regenerative practice that promises dramatic short-timeline effects across all indications is making claims the evidence does not support.

11. What if the patient asks about exosomes specifically?

Exosome therapy is reasonable adjunctively to other regenerative protocols and topically post-microneedling for cosmetic indications. The dominant clinical question is sourcing transparency — the source laboratory, lot documentation, characterization data. See the patient-facing companion Exosome Therapy in Colombia — What's Actually in That Vial? for the verification framework.

12. What documentation should I expect to receive from the regenerative practice?

At minimum: the operative or procedure note with date, indication, protocol, technique, and any intraprocedural events; the tissue processing documentation (for autologous: cell count, viability, processing technique; for allogeneic: lot number, source documentation); photographic documentation when relevant; the post-procedure protocol with activity modification, medication recommendations, and follow-up schedule; any ordered follow-up imaging or labs; and contact information for clinical consultation during the recovery period.

Cross-Linked Companion Guides (The Verification Quartet and Cluster)

• Exosome Therapy in Colombia — What's Actually in That Vial? (2026) — first piece of the verification framework (allogeneic product transparency).
• Volume Beats Credentials: The 2026 Stem Cell Clinic Verification Framework (2026) — second piece (procedural infrastructure).
• PRP Variability — What's Actually in Your Tube? (2026) — third piece (autologous product transparency).
• Medical IV Therapy in Medellín: What's Actually in Your Drip? (2026) — fourth piece in English (compounded fluid transparency).
• Sueroterapia Médica en El Poblado, Medellín (2026) — Spanish-language IV verification companion.
• Combined Peptide + Stem Cell Therapy: The Clinical Sequencing Guide (2026) — for the multi-modal protocol architecture.
• Cost-Per-Result: When PRP Beats Exosomes Beats Stem Cells (2026) — for the patient buyer decision framework.
• Verifying Your Medellín Peptide Clinic on Day 1 (2026) — for the binary credential verification.
• Peptide Therapy in Colombia: INVIMA Standards, Safety & Regulations (2026) — for the INVIMA framework.

Who This Article Is NOT For

• Physicians seeking marketing reassurance about regenerative medicine without an honest evidence-quality assessment.
• Physicians seeking to refer patients without having done appropriate first-line care or workup in their own clinic.
• Physicians who view regenerative medicine as a substitute for evidence-based standard care for serious conditions.
• Physicians who view a regenerative referral as a way to discharge a difficult patient rather than as an integrated component of the patient's care plan.
• Physicians unwilling to oversee post-procedure care or document the regenerative intervention in the patient's record.

The Bottom Line

Regenerative medicine in 2026 is a real specialty with real indications, real evidence (varying in quality by indication), real regulatory frameworks (FDA in the US, INVIMA in Colombia), and real verification questions that the referring physician can apply with the same clinical rigor as any other specialty referral.

The patient-facing verification quartet on this site (exosomes, stem cells, PRP, IV) lays out the verification questions in the patient's vocabulary. This primer translates them into the physician-to-physician vocabulary.

The framework is honest. Some regenerative interventions are well-supported. Some are preliminary. Some are experimental. Some are marketed beyond the evidence. A referring physician who can locate the proposed intervention on that gradient — and apply the verification framework to the proposed practice — can support the patient's decision substantively.

A regenerative practice that welcomes the verification questions, sends documentation back to the referring physician, and participates in post-procedure care oversight is operating as a serious specialty referral destination. A practice that resists those expectations is providing the referring physician with diagnostic information about itself.

Refer a Patient to YouMedicine

YouMedicine in El Poblado, Medellín welcomes physician-to-physician referrals from primary care, family medicine, sports medicine, dermatology, internal medicine, and other specialties.

• Physician-to-physician contact: wellness@youmedicine.co
• WhatsApp: +57 324 576 1913
• Location: El Poblado, Medellín, Colombia

In your initial referral message, please include:

• The patient's indication and relevant history
• Your specific clinical question or proposed referral protocol

Every plan is personalized. Message us on WhatsApp and we'll send your quote after reviewing your case.

• Any specific comorbidities or medications that warrant pre-procedure modification
• Your contact information and preferred mode of physician-to-physician communication

We will respond with the protocol description, INVIMA and cell processing facility documentation, the pre-procedure workup requirements list relative to the proposed protocol, the consent framework, and the documentation that will be sent back to you post-procedure.

YouMedicine — El Poblado, Medellín. Wellness starts with YOU, with appropriate clinical infrastructure behind it.